Summary

An analysis from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents [ADAPT-DES; NCT00638794] trial showed that hyporesponsiveness to clopidogrel was not independently predictive of mortality at 1-year after percutaneous coronary intervention with a drug-eluting stent. Although hyporesponsiveness to clopidogrel was associated with increased risk of stent thrombosis and myocardial infarction, it was also associated with a reduced risk of major bleeding, which has been strongly related to mortality.